No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19. This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation. The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection
Study Type
OBSERVATIONAL
Hop Claude Huriez Chu Lille
Lille, France
Frequency of MHM imbalance triggered by COVID-19
disease aggravation or metabolic decompensation, among MHM-infected patients with COVID-19.
Time frame: at 8 weeks
Number of COVID-19 patients in Gaucher's disease
Time frame: at 24 months
Number of COVID-19 patients in Urea Cycle Disorder
Time frame: at 24 months
Severity of COVID-19 infection
severity of COVID-19 infection as assessed by hospitalization; Intensive Care Unit, death
Time frame: at 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.